Immunohistochemical analysis of calpain 3: Advantages and limitations in diagnosing LGMD2A

Neuromuscular Disorders

Volumn 19, Issue 7, 2009, Pages 449-457

  Charlton, Richard ^a   Henderson, Matthew ^a   Richards, Julie ^a   Hudson, Judith ^b   Straub, Volker ^b   Bushby, Kate ^b   Barresi, Rita ^a,b  

^a NEWCASTLE DENTAL HOSPITAL   (United Kingdom)

^b INSTITUTE OF HUMAN GENETICS   (United Kingdom)

Author keywords

Calpain 3 (CAPN3); Immunohistochemistry (IHC); Limb girdle muscular dystrophy (LGMD); Western blot (WB)

Indexed keywords

CALPAIN 3; PROTEIN ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELIABILITY; SCREENING TEST;

ANTIBODY SPECIFICITY; BASE SEQUENCE; BIOLOGICAL MARKERS; CALPAIN; DOWN-REGULATION; EXONS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 67649656099     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2009.05.005     Document Type: Article

References (31)

1. Laval S.H., and Bushby K.M. Limb-girdle muscular dystrophies-from genetics to molecular pathology. Neuropathol Appl Neurobiol 30 2 (2004) 91-105
2. Pogue R., Anderson L.V., Pyle A., Sewry C., Pollitt C., Johnson M.A., et al. Strategy for mutation analysis in the autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 11 1 (2001) 80-87
3. Vainzof M., and Zatz M. Protein defects in neuromuscular diseases. Braz J Med Biol Res 36 5 (2003) 543-555
4. Pollitt C., Anderson L.V., Pogue R., Davison K., Pyle A., and Bushby K.M. The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach. Neuromuscul Disord 11 3 (2001) 287-296
5. Ibi T., Jing L., Nakao N., Minami N., and Sahashi K. A case of LGMD2A identified with both western blot analysis and immunostaining of calpain 3 in biopsied muscle. Rinsho Shinkeigaku 40 10 (2000) 1023-1027
6. Kolski H.K., Hawkins C., Zatz M., de Paula F., Biggar D., Alman B., et al. Diagnosis of limb-girdle muscular dystrophy 2A by immunohistochemical techniques. Neuropathology 28 3 (2008) 264-268
7. Anderson L.V., Davison K., Moss J.A., Richard I., Fardeau M., Tome F.M., et al. Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A. Am J Pathol 153 4 (1998) 1169-1179
8. Klinge L., Dekomien G., Aboumousa A., Charlton R., Epplen J.T., Barresi R., et al. Sarcoglycanopathies: can muscle immunoanalysis predict the genotype?. Neuromuscul Disord 18 12 (2008) 934-941
9. Anderson L.V., and Davison K. Multiplex Western blotting system for the analysis of muscular dystrophy proteins. Am J Pathol 154 4 (1999) 1017-1022
10. Baghdiguian S., Martin M., Richard I., Pons F., Astier C., Bourg N., et al. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med 5 5 (1999) 503-511
11. Taveau M., Bourg N., Sillon G., Roudaut C., Bartoli M., and Richard I. Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. Mol Cell Biol 23 24 (2003) 9127-9135
12. Groen E.J., Charlton R., Barresi R., Anderson L.V., Eagle M., Hudson J., et al. Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 130 Pt. 12 (2007) 3237-3249
13. Saenz A., Leturcq F., Cobo A.M., Poza J.J., Ferrer X., Otaegui D., et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 128 Pt. 4 (2005) 732-742
14. Fanin M., Nascimbeni A.C., Fulizio L., Trevisan C.P., Meznaric-Petrusa M., and Angelini C. Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression. Am J Pathol 163 5 (2003) 1929-1936
15. Anderson L.V., Harrison R.M., Pogue R., Vafiadaki E., Pollitt C., Davison K., et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 10 8 (2000) 553-559
16. Haravuori H., Vihola A., Straub V., Auranen M., Richard I., Marchand S., et al. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: titin is the candidate gene. Neurology 56 7 (2001) 869-877
17. Talim B., Ognibene A., Mattioli E., Richard I., Anderson L.V., and Merlini L. Normal calpain expression in genetically confirmed limb-girdle muscular dystrophy type 2A. Neurology 56 5 (2001) 692-693
18. Fanin M., Nascimbeni A.C., and Angelini C. Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations. J Med Genet 44 1 (2007) 38-43
19. Milic A., Daniele N., Lochmuller H., Mora M., Comi G.P., Moggio M., et al. A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay. Neuromuscul Disord 17 2 (2007) 148-156
20. Blazquez L., Azpitarte M., Saenz A., Goicoechea M., Otaegui D., Ferrer X., et al. Characterization of novel CAPN3 isoforms in white blood cells: an alternative approach for limb-girdle muscular dystrophy 2A diagnosis. Neurogenetics 9 3 (2008) 173-182
21. Fanin M., Nascimbeni A.C., Tasca E., and Angelini C. How to tackle the diagnosis of limb-girdle muscular dystrophy 2A. Eur J Hum Genet 17 5 (2009) 598-603
22. Kolski H.K., Hawkins C., Zatz M., de Paula F., Biggar D., Alman B., et al. Diagnosis of limb-girdle muscular dystrophy 2A by immunohistochemical techniques. Neuropathology 28 3 (2008) 264-268
23. Keira Y., Noguchi S., Minami N., Hayashi Y.K., and Nishino I. Localization of calpain 3 in human skeletal muscle and its alteration in limb-girdle muscular dystrophy 2A muscle. J Biochem 133 5 (2003) 659-664
24. Spencer M.J., and Tidball J.G. Calpain translocation during muscle fiber necrosis and regeneration in dystrophin-deficient mice. Expr Cell Res 226 2 (1996) 264-272
25. Goll D.E., Thompson V.F., Li H., Wei W., and Cong J. The calpain system. Physiol Rev 83 3 (2003) 731-801
26. Beckmann J.S., and Spencer M. Calpain 3, the "gatekeeper" of proper sarcomere assembly, turnover and maintenance. Neuromuscul Disord 18 12 (2008) 913-921
27. Fougerousse F., Bullen P., Herasse M., Lindsay S., Richard I., Wilson D., et al. Human-mouse differences in the embryonic expression patterns of developmental control genes and disease genes. Hum Mol Genet 9 2 (2000) 165-173
28. Herasse M., Ono Y., Fougerousse F., Kimura E., Stockholm D., Beley C., et al. Expression and functional characteristics of calpain 3 isoforms generated through tissue-specific transcriptional and posttranscriptional events. Mol Cell Biol 19 6 (1999) 4047-4055
29. Fougerousse F., Durand M., Suel L., Pourquie O., Delezoide A.L., Romero N.B., et al. Expression of genes (CAPN3, SGCA, SGCB, and TTN) involved in progressive muscular dystrophies during early human development. Genomics 48 2 (1998) 145-156
30. Stockholm D., Herasse M., Marchand S., Praud C., Roudaut C., Richard I., et al. Calpain 3 mRNA expression in mice after denervation and during muscle regeneration. Am J physiol 280 6 (2001) C1561-C1569
31. Ojima K., Ono Y., Doi N., Yoshioka K., Kawabata Y., Labeit S., et al. Myogenic stage, sarcomere length, and protease activity modulate localization of muscle-specific calpain. J Biol Chem 282 19 (2007) 14493-14504